_id,drug,structure,transporter,species,geneName,geneId,type,place,method,experimentalSystem,dose,route,substanceMeasured,concomitant,time,comment,parameterType,parameter,value,units,reference,source,sourceLink,year,TransporterInfo_id,fullname,structurelink
ISTE024189,Fluvoxamine Maleate,OC(=O)\C=C/C(O)=O.COCCCC\C(C1=CC=C(C=C1)C(F)(F)F)=N/OCCN,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,15 days,Oral,Digoxin,[Digoxin],,,AUC,AUC change,5,%,"FDA approval package document: Printed Labeling 020243, page:14 PDF 1215k",FDA approval package document,,1994,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024196,Ramelteon,CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,16 mq qd on 1-12 days,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC decrease,3,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021782/S-000, page:60 PDF 3065k",FDA approval package document,,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024198,Ramelteon,CCC(=O)NCC[C@@H]1CCC2=CC=C3OCCC3=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"16 mg/day, 12 days",Oral,Digoxin,[Digoxin],,,AUC,AUC decrease,3,%,"FDA approval package document: Medical/Clinical Review 021782/S-000, page:196 PDF 9492k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024199,Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,1200 mg QD for 8 days,Oral,Digoxin,[Digoxin],,,AUC,AUC decrease,4,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022416/S-000 Part 08, page:3 PDF 362k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024204,Diroximel Fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,462 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf); compared to concomitant drug alone,AUC,AUC decrease,10,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 211855/S-000, page:26 PDF 3661k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024205,Diroximel Fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,462 mg,Oral,Digoxin,[Digoxin],,AUC(0-last); compared to concomitant drug alone,AUC,AUC decrease,10,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 211855/S-000, page:26 PDF 3661k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024207,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"500 mg BID, 7d",Oral,Digoxin,[Digoxin],d14,AUC(0-tau),AUC,AUC decrease,12,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021290/S-000 Part 02, page:30 PDF 1519k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024208,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"500 mg BID, 7d",Oral,Digoxin,[Digoxin],d8,AUC(0-tau),AUC,AUC decrease,12,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021290/S-000 Part 02, page:32 PDF 1519k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024209,Prasugrel Hydrochloride,Cl.CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg for 9 days,Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC decrease,13,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022307/S-000 Part 20, page:10 PDF 1001k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024210,Prasugrel Hydrochloride,Cl.CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg for 9 days,Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC decrease,13,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022307/S-000 Part 20, page:9 PDF 1001k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024211,Prasugrel Hydrochloride,Cl.CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg for 9 days,Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC decrease,13,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022307/S-000 Part 48, page:8 PDF 858k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024212,Prasugrel Hydrochloride,Cl.CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg for 9 days,Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC decrease,13,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022307/S-000 Part 48, page:9 PDF 858k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024216,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 01, page:19 PDF 6476k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024217,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 01, page:32 PDF 6476k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024218,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 01, page:36 PDF 6476k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024219,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"30 mg/d, 14 days",Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 08, page:23 PDF 5992k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024220,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 11, page:21 PDF 8090k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024221,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 11, page:57 PDF 8090k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024222,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 11, page:94 PDF 8090k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024223,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 18, page:35 PDF 4368k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024224,Paroxetine Hydrochloride,Cl.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 19, page:49 PDF 7701k",FDA approval package document,,1992,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024225,Paroxetine Mesylate,CS(O)(=O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC decrease,15,%,"FDA approval package document: Approval Package 021299/S-001, page:9 PDF 3348k",FDA approval package document,,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024226,Paroxetine Mesylate,CS(O)(=O)=O.FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC decrease,15,%,"FDA approval package document: Printed Labeling 021299/S-000, page:10 PDF 1041k",FDA approval package document,,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024227,Tegaserod Maleate,OC(=O)\C=C\C(O)=O.CCCCCNC(=N)N\N=C/C1=CNC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,6 mg BID for 6 days,Oral,Digoxin,[Digoxin],,,AUC,AUC decrease,15,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021200/S-000 Part 01, page:13 PDF 958k",FDA approval package document,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024304,Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg/d,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,1,%,"FDA approval package document: Label 207999/S-000 Part 01, page:13 PDF 355k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024305,Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg/d,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,1,%,"FDA approval package document: Label 207999/S-000, page:12 PDF 581k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024312,Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C(Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,compared to concominant drug alone,AUC,AUC increase,6,%,"EMA approval document: ANNEX I, page:7 PDF 370k",EMA approval document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024313,Saxagliptin Hydrochloride,Cl.[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)[C@H](N)C(=O)N1[C@@H](C[C@]2([H])C[C@]12[H])C#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"10 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,"AUC(0-tau), steady-state",AUC,AUC increase,6,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022350/S-000 Part 01, page:66 PDF 5032k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024314,Edoxaban Tosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CN1CCC2=C(C1)SC(=N2)C(=O)N[C@@H]1C[C@H](CC[C@@H]1NC(=O)C(=O)NC1=NC=C(Cl)C=C1)C(=O)N(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"60 mg/d, for 14 days",Oral,Digoxin,[Digoxin],,compared to concominant drug alone,AUC,AUC increase,7,%,"EMA approval document: ANNEX I, page:11 PDF 495k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024318,Cobicistat,CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg once daily for 10 days,Oral,Digoxin,[Digoxin],0-inf,,AUC,AUC increase,7.7,%,"EMA approval document: Assessment Report EMA/CHMP/609914/2013; EMEA/H/C/002572/0000, page:34 PDF 1120k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024323,Pexidartinib Hydrochloride,Cl.FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,1800 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf); compared to concomitant drug alone; geometric mean,AUC,AUC increase,9,%,"FDA approval package document: Approval Package 211810/S-000 Part 03, page:12 PDF 629k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024324,Pexidartinib Hydrochloride,Cl.FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,1800 mg,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,9,%,"FDA approval package document: Label 211810/S-001, page:15 PDF 424k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024325,Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC increase,9,%,"EMA approval document: ANNEX I, page:9 PDF 482k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024326,Pantoprazole Sodium,[Na+].COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,40 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,10.4,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 020988/S-000, page:46 PDF 1747k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024327,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg,Oral,Digoxin,[Digoxin],,"AUC(0-tau), steady state",AUC,AUC increase,11,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021061, page:30 PDF 1099k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024329,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg,Oral,Digoxin,[Digoxin],,"AUC(0-tau), steady state",AUC,AUC increase,11,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021061/S-000; 021062/S-000, page:31 PDF 1141k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024334,Sitagliptin Phosphate,O.OP(O)(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,11,%,"EMA approval document: ANNEX I, page:5 PDF 444k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024336,Sitagliptin Phosphate,O.OP(O)(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,11,%,"EMA approval document: ANNEX I, page:5 PDF 457k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024337,Sitagliptin Phosphate,O.OP(O)(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=C(F)C=C(F)C(F)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,11,%,"EMA approval document: ANNEX I, page:5 PDF 458k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024340,Zanubrutinib,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,160 mg,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,11.3,%,"FDA approval package document: Approval Package 213217/S-000 Part 02, page:40 PDF 15322k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024346,Lurasidone Hydrochloride,Cl.[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,120 mg once daily on days 6-14,Oral,Digoxin,[Digoxin],,AUC(0-24h),AUC,AUC increase,13,%,DOI:10.1515/dmdi20140005   ISSN:07925077   JOURNAL:Drug Metabolism and Drug Interactions   PAGES:191   VOLUME:29,Literature,http://dx.doi.org/10.1515/dmdi-2014-0005,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024347,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"12.5 mg/d for 2 days, then 25 mg qd for 12 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC increase,14,%,"FDA approval package document: Administrative documents 020297 Part 03, page:60 PDF 2287k",FDA approval package document,,1995,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024348,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Administrative documents 020297, page:20 PDF 2154k",FDA approval package document,,1995,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024349,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Administrative documents 020297, page:58 PDF 2103k",FDA approval package document,,1995,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024350,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"12.5 mg/d for 2 days, then 25 mg/d for 12 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC increase,14,%,"FDA approval package document: Medical/Clinical Review 020297 Part 01, page:9 PDF 1734k",FDA approval package document,,1993,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024351,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Printed Labeling 020297/S-007, page:5 PDF 993k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024352,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Printed Labeling 020297/S-009, page:5 PDF 1108k",FDA approval package document,,2003,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024353,Carvedilol Phosphate,O.OP(O)(O)=O.COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Medical/Clinical Review 022012/S-000 Part 01, page:75 PDF 7285k",FDA approval package document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024354,Carvedilol Phosphate,O.OP(O)(O)=O.COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 14 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,14,%,"FDA approval package document: Printed Labeling 022012/S-000, page:4 PDF 2158k",FDA approval package document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024359,Atorvastatin Calcium,[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(C2=CC=CC=C2)=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,80 mg QD for 14 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,15,%,"FDA approval package document: Label 020702/S-060, page:14 PDF 744k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024360,Nefazodone Hydrochloride,Cl.CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,200 mg BID for 9 days,Oral,Digoxin,[Digoxin],,AUC(TAU),AUC,AUC increase,15,%,"FDA approval package document: Medical Officer Review 020152, page:3 PDF 856k",FDA approval package document,,1994,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024361,Nefazodone Hydrochloride,Cl.CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,200 mg BID for 9 days,Oral,Digoxin,[Digoxin],,AUC(TAU),AUC,AUC increase,15,%,"FDA approval package document: Medical Officer Review 020152, page:8 PDF 856k",FDA approval package document,,1994,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024362,Nefazodone Hydrochloride,Cl.CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,200 mg BID for 9 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,15,%,"FDA approval package document: Printed Labeling 020152/S-009, S-010, page:10 PDF 1750k",FDA approval package document,,1997,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024370,Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,18,%,"FDA approval package document: Label 212725/S-001, page:17 PDF 1036k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024371,Entrectinib,CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=C2C=C(CC2=CC(F)=CC(F)=C2)C=C3)C(NC2CCOCC2)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,18,%,"FDA approval package document: Label 212726/S-001, page:17 PDF 1034k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024373,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg,Oral,Digoxin,[Digoxin],,AUC(0-48),AUC,AUC increase,19,%,"FDA approval package document: Administrative documents 020297 Part 03, page:60 PDF 2287k",FDA approval package document,,1995,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024374,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC increase,19,%,"FDA approval package document: Administrative documents 020297 Part 04, page:68 PDF 1941k",FDA approval package document,,1995,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024375,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg,Oral,Digoxin,[Digoxin],,AUC(0-48),AUC,AUC increase,19,%,"FDA approval package document: Medical/Clinical Review 020297 Part 01, page:9 PDF 1734k",FDA approval package document,,1993,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024376,Carvedilol,COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC increase,19,%,"FDA approval package document: Medical/Clinical Review 020297 Part 02, page:46 PDF 1538k",FDA approval package document,,1993,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024377,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Label 021061/S-000; 021062/S-000, page:6 PDF 286k",FDA approval package document,,,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024378,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg/day for 7D,Oral,Digoxin,[Digoxin],,in 8 of 11 healthy volunteers,AUC,AUC increase,19,%,"FDA approval package document: Label 021061/S-024, S-023; 021062/S-026, S-027, S-037, page:11 PDF 673k",FDA approval package document,,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024379,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Other Important Information from FDA 021062/S-000; 021061/S-000; 021678/S-000, page:12 PDF 644k",FDA approval package document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024380,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021061, page:7 PDF 916k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024381,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021061/S-000; 021062/S-000, page:7 PDF 918k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024382,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021061/S-007; 021062/S-008 Part 01, page:9 PDF 1108k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024383,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021061/S-007; 021062/S-008 Part 02, page:10 PDF 1062k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024384,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021062/S-011, S-017; 021404/S-000; 021405/S-000; 021061/S-010, S-016, page:13 PDF 2667k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024385,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg/d, 7 days",Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Printed Labeling 021678/S-000, page:13 PDF 2842k",FDA approval package document,,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024386,Rabeprazole Sodium,[Na+].COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19,%,"FDA approval package document: Approval Package 020973/S-009 Part 01, page:18 PDF 829k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024393,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg once daily for 7 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,20,%,"EMA approval document: ANNEX I, page:8 PDF 557k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024394,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,20,%,"EMA approval document: Assessment Report EMA/374133/2013; EMEA/H/C/002649/0000, page:36 PDF 1815k",EMA approval document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024396,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,20,%,"FDA approval package document: Label 022275/S-007, page:10 PDF 717k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024397,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"60 mg/d, on Days 8-12",Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,20,%,"FDA approval package document: Label 204441/S-000, page:13 PDF 469k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024398,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,20,%,"FDA approval package document: Letter 022275/S-007, page:2 PDF 288k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024403,Istradefylline,CCN1C(=O)N(CC)C2=C(N(C)C(/C=C/C3=CC=C(OC)C(OC)=C3)=N2)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,AUC(0-inf); compared to concomitant drug alone,AUC,AUC increase,21,%,"FDA approval package document: Label 022075/S-001, page:6 PDF 821k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024427,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC increase,25,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:51 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024428,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC increase,25,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:81 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024431,Isavuconazonium Sulfate,OS([O-])(=O)=O.CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C2=NC(=CS2)C2=CC=C(C=C2)C#N)C2=C(F)C=CC(F)=C2)N=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,200 mg/d,Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC increase,25,%,"FDA approval package document: Review 207500/S-000; 207501/S-000 Part 06, page:9 PDF 6846k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024437,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,27,%,"EMA approval document: ANNEX I, page:5 PDF 435k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024438,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg qd,Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC increase,27,%,"EMA approval document: Assessment Report EMA/706651/2012; EMEA/H/C/002388, page:112 PDF 3434k",EMA approval document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024439,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC increase,27,%,"EMA approval document: Assessment Report EMA/706651/2012; EMEA/H/C/002388, page:29 PDF 3434k",EMA approval document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024446,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"40 mg/d, for 11 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC increase,27,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:132 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024448,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"40 mg/d, for 11 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC increase,27,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:296 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024457,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,30,%,"FDA approval package document: Approval Package 020689 Part 08, page:61 PDF 6416k",FDA approval package document,,1997,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024458,Mibefradil,COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=CC=CC=C3N2)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg/d for 7 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,30,%,"FDA approval package document: Approval Package 020689 Part 08, page:67 PDF 6416k",FDA approval package document,,1997,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024461,Rolapitant Hydrochloride,Cl.C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"180 mg, single",Oral,Digoxin,[Digoxin],,compared to concominant drug alone,AUC,AUC increase,30,%,"EMA approval document: ANNEX I, page:5 PDF 923k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024463,Rolapitant Hydrochloride,Cl.C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"180 mg, on Day 1",Oral,Digoxin,[Digoxin],Day 1,,AUC,AUC increase,30,%,"FDA approval package document: Label 206500/S-000, page:11 PDF 684k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024464,Rolapitant Hydrochloride,Cl.C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C1=CC=CC=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"180 mg, on Day 1",Oral,Digoxin,[Digoxin],,1 day; compared to concominant drug alone,AUC,AUC increase,30,%,"FDA approval package document: Label 206500/S-000, page:11 PDF 684k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024469,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,240 mg,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,32,%,"EMA approval document: ANNEX I, page:8 PDF 501k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024471,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"240 mg, multiple",Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,32,%,"EMA approval document: Public Assessment Report EMA/CHMP/525204/2018; EMEA/H/C/004030/0000, page:62 PDF 3885k",EMA approval document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024472,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,compared to concominant drug alone,AUC,AUC increase,32,%,"FDA approval package document: Approval Package 208051/S-000 Part 04, page:34 PDF 4053k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024473,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"241 mg, multiple",Oral,Digoxin,[Digoxin],,mean; compared to concomitant drug alone,AUC,AUC increase,32,%,"FDA approval package document: Label 208051/S-001, page:16 PDF 520k",FDA approval package document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024475,Quinine Sulfate,O.OS(O)(=O)=O.[H][C@@]12CCN(C[C@H]1C=C)[C@@]([H])(C2)[C@H](O)C1=CC=NC2=C1C=C(OC)C=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,750 mg/d,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC increase,33,%,"FDA approval package document: Label 021799/S-021, page:9 PDF 632k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024480,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg, for 17 days",Oral,Digoxin,[Digoxin],,"AUC(0-last), in CYP2D6 poor metabolizers",AUC,AUC increase,37,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205494/S-000, page:113 PDF 24157k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024484,Fostamatinib disodium,[Na+].COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP([O-])([O-])=O)C4=N3)=N2)=CC(OC)=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg bid, on Days 9-15",Oral,Digoxin,[Digoxin],,mean; compared to concomitant drug alone; steady-state,AUC,AUC increase,37,%,"FDA approval package document: Approval Package 209299/S-000 Part 02, page:62 PDF 5888k",FDA approval package document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024485,Fostamatinib disodium,[Na+].COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)N(COP([O-])([O-])=O)C4=N3)=N2)=CC(OC)=C1OC,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg BID,Oral,Digoxin,[Digoxin],,compared to concomitant drug alone,AUC,AUC increase,37,%,"FDA approval package document: Label 209299/S-001, page:13 PDF 751k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024490,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"150 mg, for 17 days",Oral,Digoxin,[Digoxin],,"AUC(0-last), in CYP2D6 extensive, intermediate, ultra-rapid metabolizers",AUC,AUC increase,41,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205494/S-000, page:113 PDF 24157k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024491,Conivaptan Hydrochloride,Cl.CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,40 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,43,%,"FDA approval package document: Label 021697/S-001, page:8 PDF 578k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024492,Conivaptan Hydrochloride,Cl.CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,40 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,43,%,"FDA approval package document: Printed Labeling 021697/S-000, page:8 PDF 1281k",FDA approval package document,,2005,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024500,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100-150 mg, for 17 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC increase,49,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205494/S-000, page:113 PDF 24157k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024515,Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,60,%,"EMA approval document: Scientific Discussion, page:19 PDF 371k",EMA approval document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024520,Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,61,%,"EMA approval document: ANNEX I, page:15 PDF 1002k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024524,Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,61,%,"EMA approval document: ANNEX I, page:54 PDF 1002k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024525,Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,61,%,"EMA approval document: ANNEX I, page:93 PDF 1002k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024528,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-t),AUC,AUC increase,62,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:51 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024529,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-t),AUC,AUC increase,62,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:81 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024533,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg/day for 7D,Oral,Digoxin,[Digoxin],,in 1 of 11 healthy volunteers,AUC,AUC increase,66,%,"FDA approval package document: Label 021061/S-024, S-023; 021062/S-026, S-027, S-037, page:11 PDF 673k",FDA approval package document,,2004,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024545,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg BID for 3 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,86,%,"EMA approval document: ANNEX I, page:15 PDF 1136k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024547,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg BID for 3 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,86,%,"EMA approval document: ANNEX I, page:49 PDF 1136k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024557,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC increase,96,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:51 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024558,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC increase,96,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:81 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024559,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC increase,96,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022526/S-000 Part 03, page:82 PDF 23213k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024576,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 or 200 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,150,%,"FDA approval package document: Cross Discipline Team Leader Review 022425/S-000 Part 01, page:10 PDF 1053k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024585,Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg,Oral,Digoxin,[Digoxin],,0-last,AUC,AUC increase,168,%,DOI:10.1007/s40262141612   ISSN:03125963   JOURNAL:Clinical Pharmacokinetics   PAGES:837   VOLUME:53,Literature,http://dx.doi.org/10.1007/s40262-014-0161-2,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024593,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"300 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC increase,~20,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204042/S-000 Part 04, page:14 PDF 3602k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024598,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"240 mg/d, multiple",Oral,Digoxin,[Digoxin],,compared to concominant drug alone; geometric mean,AUC,AUC increase,~32,%,"FDA approval package document: Approval Package 208051/S-000 Part 04, page:43 PDF 4053k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024602,Gemifloxacin Mesylate,CS(O)(=O)=O.CO\N=C1/CN(CC1CN)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=N1)C(O)=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg/d for 7 days,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,19-104,%,"FDA approval package document: Administrative documents 021158/S-000 Part 04, page:14 PDF 1370k",FDA approval package document,,2000,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024607,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,66-104,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021061, page:31 PDF 1099k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024609,Gatifloxacin,COC1=C(N2CCNC(C)C2)C(F)=CC2=C1N(C=C(C(O)=O)C2=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC increase,66-104,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021061/S-000; 021062/S-000, page:32 PDF 1141k",FDA approval package document,,1999,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024619,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"500 mg BID, 7d",Oral,Digoxin,[Digoxin],d14,AUC(0-24h),AUC,AUC ratio,88,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021290/S-000 Part 02, page:30 PDF 1519k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024628,Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"150 mg, bid, on Days 5-13, qd on Day 14",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,100,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205858/S-000 Part 01, page:37 PDF 8022k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024629,Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"150 mg, bid for 9 days, qd on Day 10",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,100,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206545/S-000, page:37 PDF 11574k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024631,Dabigatran Etexilate Mesylate,CS(O)(=O)=O.CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg bid,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,101,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022512/S-000 Part 03, page:8 PDF 424k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024634,Azilsartan Kamedoxomil,[K+].CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC([O-])N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,80 mg QD,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC ratio,102.87,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 200796/S-000 Part 02, page:31 PDF 2223k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024637,Sarecycline Hydrochloride,Cl.[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg,Oral,Digoxin,[Digoxin],,AUC(0-tau); steady-state; with/without parent ratio,AUC,AUC ratio,103.2,%,"FDA approval package document: Approval Package 209521 Part 05, page:12 PDF 3896k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024638,Sarecycline Hydrochloride,Cl.[H][C@@]12CC3=C(CN(C)OC)C=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg,Oral,Digoxin,[Digoxin],,AUC(0-tau); steady-state; with/without parent ratio,AUC,AUC ratio,103.2,%,"FDA approval package document: Approval Package 209521/S-000 Part 04, page:12 PDF 3904k",FDA approval package document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024639,Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"150 mg, bid, on Days 5-13, qd on Day 14",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,104,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205858/S-000 Part 01, page:37 PDF 8022k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024641,Vorapaxar Sulfate,OS(O)(=O)=O.[H][C@@]12C[C@@H](CC[C@@]1([H])[C@H](\C=C\C1=CC=C(C=N1)C1=CC=CC(F)=C1)[C@]1([H])[C@@H](C)OC(=O)[C@]1([H])C2)NC(=O)OCC,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"2.5 mg, on Days 1-6, 40 mg, on Day 7",Oral,Digoxin,[Digoxin],,AUC(0-t),AUC,AUC ratio,105,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204886/S-000 Part 01, page:65 PDF 7820k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024642,Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"500 mg BID, 7d",Oral,Digoxin,[Digoxin],d8,AUC(0-24h),AUC,AUC ratio,106,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021290/S-000 Part 02, page:30 PDF 1519k",FDA approval package document,,2001,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024655,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg on days 1-7,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,119.5,%,DOI:10.5414/CP202157   ISSN:09461965   JOURNAL:International Journal of Clinical Pharmacology and Therapeutics   PAGES:41   VOLUME:53,Literature,http://dx.doi.org/10.5414/CP202157,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024656,Vandetanib,COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=CC=C(Br)C=C3F)C2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg,Oral,Digoxin,[Digoxin],,0-last,AUC,AUC ratio,123,%,DOI:10.1007/s40262141612   ISSN:03125963   JOURNAL:Clinical Pharmacokinetics   PAGES:837   VOLUME:53,Literature,http://dx.doi.org/10.1007/s40262-014-0161-2,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024657,Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"150 mg, bid for 9 days, qd on Day 10",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,124,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 206545/S-000, page:37 PDF 11574k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024662,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"240 mg/d, multiple",Oral,Digoxin,[Digoxin],,with/without parent ratio; geometric mean,AUC,AUC ratio,132,%,"FDA approval package document: Approval Package 208051/S-000 Part 04, page:44 PDF 4053k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024663,Neratinib Maleate,OC(=O)\C=C/C(O)=O.CCOC1=C(NC(O)\C=C\CN(C)C)C=C2C(=C1)N=CC(C#N)=C2NC1=CC=C(CC2=CC=CC=N2)C(Cl)=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"240 mg/d, multiple",Oral,Digoxin,[Digoxin],,AUC(0-tau); with/without parent ratio; geometric mean,AUC,AUC ratio,135,%,"FDA approval package document: Approval Package 208051/S-000 Part 04, page:44 PDF 4053k",FDA approval package document,,2016,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024664,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100-150 mg, for 17 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,148.6,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205494/S-000, page:114 PDF 24157k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024665,Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"750 mg, on Days 8-23",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,184.7,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201917/S-000 Part 04, page:10 PDF 4029k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024666,Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"750 mg, on Days 8-23",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,184.7,%,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201917/S-000 Part 04, page:9 PDF 4029k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024669,Rucaparib Camsylate,[H][C@@]12CC[C@@](CS(O)(=O)=O)(C(=O)C1)C2(C)C.CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,AUC(0-last); with/without parent geometric mean ratio,AUC,AUC ratio,1.2,dimensionless,"EMA approval document: Assessment Report EMA/902679/2019; EMEA/H/C/004272/II/0001, page:15 PDF 5694k",EMA approval document,,2018,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024675,Letermovir,COC1=CC=CC(=C1)N1CCN(CC1)C1=NC2=C(C=CC=C2F)[C@H](CC(O)=O)N1C1=C(OC)C=CC(=C1)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,240 mg bid,Oral,Digoxin,[Digoxin],,with/without parent ratio,AUC,AUC ratio,0.88,fold,"FDA approval package document: Label 209939/S-001; 209940/S-001, page:17 PDF 752k",FDA approval package document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024678,Ticlopidine Hydrochloride,Cl.ClC1=CC=CC=C1CN1CCC2=C(C1)C=CS2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"250 mg bid, 10 days",Oral,Digoxin,[Digoxin],,AUC(0-8h),AUC,AUC ratio,0.914,fold,"FDA approval package document: Approval Package 019979/S-009 Part 10, page:12 PDF 3930k",FDA approval package document,,1991,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024679,Aprepitant,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"125 mg on D7, 80 mg on D8-11",Oral,Digoxin,[Digoxin],Day 11,,AUC,AUC ratio,0.93,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021549/S-000, page:50 PDF 1956k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024685,Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,0.96,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022416/S-000 Part 08, page:2 PDF 362k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024686,Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,1200 mg QD for 8 days,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC ratio,0.96,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022416/S-000 Part 14, page:27 PDF 4324k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024687,Eslicarbazepine Acetate,CC(=O)O[C@H]1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,1200 mg QD for 8 days,Oral,Digoxin,[Digoxin],,AUC(0-tau),AUC,AUC ratio,0.96,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022416/S-000 Part 14, page:28 PDF 4324k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024688,Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"4 mg, bid, on Days 9-16",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC ratio,0.984,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022206/S-000, page:34 PDF 6148k",FDA approval package document,,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024689,Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"4 mg, bid, on Days 9-16",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC ratio,0.984,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022206/S-000, page:79 PDF 6148k",FDA approval package document,,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024690,Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"4 mg, bid, on Days 9-16",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC ratio,0.984,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022206/S-000, page:81 PDF 6148k",FDA approval package document,,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024691,Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=C(OCC(F)(F)F)C=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"4 mg, SS",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,0.984,fold,"FDA approval package document: Medical/Clinical Review 022206/S-000 Part 01, page:61 PDF 5541k",FDA approval package document,,2007,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024692,Aprepitant,C[C@@H](O[C@H]1OCCN(CC2=NC(=O)NN2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"125 mg on D7, 80 mg on D8-11",Oral,Digoxin,[Digoxin],Day 7,,AUC,AUC ratio,0.99,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 021549/S-000, page:50 PDF 1956k",FDA approval package document,,2002,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024693,Dapagliflozin Propanediol,CC(O)CO.CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"20 mg on Day 1, 10 mg QD for Days 2-8",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,1,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 202293/S-000 Part 03, page:45 PDF 4526k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024696,Lefamulin Acetate,CC(O)=O.[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,AUC(0-t); with/without parent ratio,AUC,AUC ratio,1,fold,"FDA approval package document: Approval Package 211672/S-000 Part 07, page:10 PDF 839k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024698,Linagliptin,CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,5 mg qd for 6 days,Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC ratio,1.01,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201280/S-000 Part 02, page:44 PDF 1538k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024699,Roflumilast,FC(F)OC1=CC=C(C=C1OCC1CC1)C(=O)NC1=C(Cl)C=NC=C1Cl,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,500 ug qd on days 1-14,Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,1.01,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022522/S-000 Part 05, page:48 PDF 4852k",FDA approval package document,,2010,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024703,Lacosamide,COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,200 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.0241,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022253/S-000; 022254/S-000 Part 01, page:15 PDF 6072k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024709,Saxagliptin Hydrochloride,Cl.[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)[C@H](N)C(=O)N1[C@@H](C[C@]2([H])C[C@]12[H])C#N,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,10 mg on Days 1-7,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.06,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022350/S-000 Part 01, page:40 PDF 5032k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024715,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"200 mg, Q12h, 6 days",Oral,Digoxin,[Digoxin],,AUC(0-3h),AUC,AUC ratio,1.08,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 02, page:33 PDF 752k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024716,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"200 mg, Q12h, Days 1-11",Oral,Digoxin,[Digoxin],,AUC(0-3h),AUC,AUC ratio,1.08,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 03, page:41 PDF 1205k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024719,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"200 mg, Q12h, Days 1-11",Oral,Digoxin,[Digoxin],,AUC(0-24 h),AUC,AUC ratio,1.09,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 03, page:41 PDF 1205k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024720,Lefamulin Acetate,CC(O)=O.[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,with/without parent ratio,AUC,AUC ratio,1.11,fold,"EMA approval document: ANNEX I, page:5 PDF 560k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024721,Lefamulin Acetate,CC(O)=O.[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf); with/without parent geometric mean ratio,AUC,AUC ratio,1.11,fold,"EMA approval document: Public Assessment Report EMA/325848/2020; EMEA/H/C/005048/0000, page:65 PDF 7576k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024722,Lefamulin Acetate,CC(O)=O.[H][C@@]12C(=O)CC[C@]11CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,600 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf); with/without parent geometric mean ratio,AUC,AUC ratio,1.11,fold,"FDA approval package document: Approval Package 211672/S-000 Part 05, page:135 PDF 1578k",FDA approval package document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024725,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"200 mg, Q12h, 6 days",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,1.12,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 02, page:33 PDF 752k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024726,Fidaxomicin,[H][C@]1(C\C=C(C)\C=C(C)\[C@H](O[C@]2([H])OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]2O)[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O1)[C@@H](C)O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"200 mg, Q12h, Days 1-11",Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,1.12,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201699/S-000 Part 03, page:41 PDF 1205k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024729,Lurasidone Hydrochloride,Cl.[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,120 mg once daily on days 6-14,Oral,Digoxin,[Digoxin],,AUC(0-24h),AUC,AUC ratio,1.13,fold,DOI:10.1515/dmdi20140005   ISSN:07925077   JOURNAL:Drug Metabolism and Drug Interactions   PAGES:191   VOLUME:29,Literature,http://dx.doi.org/10.1515/dmdi-2014-0005,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024733,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"60 mg/d, on Days 1, 12-16",Oral,Digoxin,[Digoxin],,"AUC(0-t), steady-state",AUC,AUC ratio,1.178,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022275/S-000 Part 05, page:61 PDF 9807k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024737,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,60 mg qd on Days 8-12,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.18,fold,"FDA approval package document: Medical/Clinical Review 022275/S-000 Part 01, page:75 PDF 6547k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024742,Canagliflozin,O.CC1=C(CC2=CC=C(S2)C2=CC=C(F)C=C2)C=C(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"300 mg/d, for 7 days",Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC ratio,1.2,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204042/S-000 Part 04, page:13 PDF 3602k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024743,Rucaparib Camsylate,[H][C@@]12CC[C@@](CS(O)(=O)=O)(C(=O)C1)C2(C)C.CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=CC(F)=CC(N1)=C23,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"600 mg bid, steady-state",Oral,Digoxin,[Digoxin],,AUC(0-72h); compared to concomitant drug alone,AUC,AUC ratio,1.2,fold,"EMA approval document: ANNEX I, page:6 PDF 564k",EMA approval document,,2019,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024749,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"60 mg/d, on Days 1, 12-16",Oral,Digoxin,[Digoxin],,steady-state,AUC,AUC ratio,1.2,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022275/S-000 Part 06, page:2 PDF 4892k",FDA approval package document,,2008,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024752,Daclatasvir Dihydrochloride,Cl.COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,60 mg/d,Oral,Digoxin,[Digoxin],,with/without parent ratio of geometric means,AUC,AUC ratio,1.27,fold,"EMA approval document: ANNEX I, page:14 PDF 476k",EMA approval document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024753,Daclatasvir Dihydrochloride,Cl.COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,60 mg/d,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.27,fold,"FDA approval package document: Label 206843/S-000, page:13 PDF 456k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024754,Daclatasvir Dihydrochloride,Cl.COC(=O)NC(C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)C(NC(=O)OC)C(C)C,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,60 mg/d,Oral,Digoxin,[Digoxin],,with/without parent ratio,AUC,AUC ratio,1.27,fold,"FDA approval package document: Label 206843/S-000, page:13 PDF 456k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024757,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"40 mg/d, for 11 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,1.27,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:132 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024758,Suvorexant,C[C@@H]1CCN(CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"40 mg/d, for 11 days",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,1.27,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 204569/S-000, page:296 PDF 40405k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024764,Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.3,fold,"FDA approval package document: Label 022275/S-005, page:10 PDF 477k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024773,Simeprevir Sodium,[Na+].[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg/d,Oral,Digoxin,[Digoxin],,least squares mean ratio with/without parent,AUC,AUC ratio,1.39,fold,"EMA approval document: ANNEX I, page:8 PDF 552k",EMA approval document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024774,Simeprevir Sodium,[Na+].[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](C[C@@]1([H])C(=O)N(C)CCCC\C=C/2)OC1=CC(=NC2=C(C)C(OC)=CC=C12)C1=NC(=CS1)C(C)C)C(=O)[N-]S(=O)(=O)C1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,150 mg QD for 7 days,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,1.39,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 205123/S-000 Part 03, page:5 PDF 276k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024783,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"127 mg, bid",Oral,Digoxin,[Digoxin],,"extensive, intermediate metabolizers",AUC,AUC ratio,1.5,fold,"FDA approval package document: Label 205494/S-000, page:15 PDF 538k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024784,Eliglustat Tartrate,O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)C1=CC=C2OCCOC2=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"84 mg, bid",Oral,Digoxin,[Digoxin],,poor metabolizers,AUC,AUC ratio,1.5,fold,"FDA approval package document: Label 205494/S-000, page:15 PDF 538k",FDA approval package document,,2014,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024788,Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg,Oral,Digoxin,[Digoxin],,with/without parent ratio,AUC,AUC ratio,1.5,fold,"FDA approval package document: Label 213411/S-001, page:13 PDF 999k",FDA approval package document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024801,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 5 days",Oral,Digoxin,[Digoxin],,AUC(0-inf); compared to concominant drug alone,AUC,AUC ratio,2,fold,"FDA approval package document: Label 022526/S-000, page:15 PDF 830k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024802,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,100 mg,Oral,Digoxin,[Digoxin],,AUC(0-inf),AUC,AUC ratio,2,fold,"FDA approval package document: Label 022526/S-000, page:16 PDF 830k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024803,Flibanserin,FC(F)(F)C1=CC=CC(=C1)N1CCN(CC1)CCN1C(=O)NC2=C1C=CC=C2,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"100 mg/d, for 5 days",Oral,Digoxin,[Digoxin],,AUC(0-inf); compared to concominant drug alone,AUC,AUC ratio,2,fold,"FDA approval package document: Label 022526/S-000, page:16 PDF 830k",FDA approval package document,,2015,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024813,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"EMA approval document: ANNEX I, page:8 PDF 494k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024814,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"EMA approval document: Assessment Report EMEA/H/C/001043, page:20 PDF 476k",EMA approval document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024815,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"EMA approval document: Withdrawal Public Statement EMEA/CHMP/370798/2006, page:17 PDF 265k",EMA approval document,,2006,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024816,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg BID,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022425/S-000 Part 02, page:46 PDF 2612k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024817,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"FDA approval package document: Letter 022425/S-004, page:1 PDF 259k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024818,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"FDA approval package document: Letter 022425/S-012, page:12 PDF 836k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024819,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"FDA approval package document: Medical/Clinical Review 022425/S-000 Part 01, page:48 PDF 4927k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024820,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.5,fold,"FDA approval package document: Medical/Clinical Review 022425/S-000 Part 01, page:7 PDF 4927k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024822,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,400 mg BID,Oral,Digoxin,[Digoxin],,AUC(0-24),AUC,AUC ratio,2.57,fold,Briefing 4417 Part 01 (Cardiovascular and Renal Drugs Advisory Committee) PDF 21354k,Advisory Committee,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024825,Lapatinib Ditosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.8,fold,"FDA approval package document: Label 022059/S-013, page:10 PDF 939k",FDA approval package document,,2012,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024826,Lapatinib Ditosylate,O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,2.8,fold,"FDA approval package document: Label 022059/S-016, S-017, page:12 PDF 861k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024833,Alogliptin Benzoate,OC(=O)C1=CC=CC=C1.CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,25 mg qd for 10 days,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,~1.0,fold,"FDA approval package document: Label 022271/S-000, page:14 PDF 2820k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024836,Valbenazine Tosylate,CC1=CC=C(C=C1)S(O)(=O)=O.[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCC1=CC(OC)=C(OC)C=C21,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,compared to concominant drug alone,AUC,AUC ratio,~1.4,fold,"FDA approval package document: Medical/Clinical Review 209241/S-000 Part 03, page:18 PDF 908k",FDA approval package document,,2017,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024837,Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,300 mg,Oral,Digoxin,[Digoxin],,"AUC(0-inf); compared to concomitant drug alone, geometric mean",AUC,AUC ratio,~1.5,fold,"FDA approval package document: Approval Package 213411/S-000 Part 04, page:20 PDF 6555k",FDA approval package document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024838,Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,960 mg,Oral,Digoxin,[Digoxin],,AUC(0-last); compared to concomitant drug alone,AUC,AUC ratio,~1.8,fold,"EMA approval document: Risk Management Plan Summary, page:9 PDF 93k",EMA approval document,,2020,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024840,Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"750 mg, q8h, on Days 8-23",Oral,Digoxin,[Digoxin],,AUC(0-last),AUC,AUC ratio,~2,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 201917/S-000 Part 01, page:56 PDF 2130k",FDA approval package document,,2011,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024848,Lurasidone Hydrochloride,Cl.[H][C@@]12[C@H]3CC[C@H](C3)[C@]1([H])C(=O)N(C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC3=C1C=CC=C3)C2=O,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,,Oral,Digoxin,[Digoxin],,,AUC,AUC ratio,<1.5,fold,"FDA approval package document: Label 200603/S-009, S-013, page:17 PDF 827k",FDA approval package document,,2013,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure
ISTE024853,Dronedarone Hydrochloride,Cl.CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,MDR1,Human,ABCB1,5243,Inhibitor,In Vivo,In Vivo,Not applicable,"400 mg BID, 10 days",Oral,Digoxin,[Digoxin],,steady state,AUC,AUC ratio,2.03-2.57,fold,"FDA approval package document: Clinical Pharmacology and Biopharmaceutics Review 022425/S-000 Part 03, page:73 PDF 4017k",FDA approval package document,,2009,IST129,Multidrug resistance protein 1,https://www.uniprot.org/uniprotkb/P08183/entry#structure